Institution
Tabriz University of Medical Sciences
Education•Tabriz, Iran•
About: Tabriz University of Medical Sciences is a education organization based out in Tabriz, Iran. It is known for research contribution in the topics: Population & Cancer. The organization has 11499 authors who have published 17525 publications receiving 241099 citations.
Topics: Population, Cancer, Solubility, Cancer cell, Randomized controlled trial
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The consumption of probiotic yogurt improved fasting blood glucose and antioxidant status in type 2 diabetic patients and suggest that probiotics are a promising agent for diabetes management.
523 citations
••
TL;DR: In this review, the main applications and liposome-based commercial products that are currently used in the medical field are summarized.
Abstract: Liposomes provide an established basis for the sustainable development of different commercial products for treatment of medical diseases by the smart delivery of drugs. The industrial applications include the use of liposomes as drug delivery vehicles in medicine, adjuvants in vaccination, signal enhancers/carriers in medical diagnostics and analytical biochemistry, solubilizers for various ingredients as well as support matrices for various ingredients and penetration enhancers in cosmetics.In this review, we summarize the main applications and liposome-based commercial products that are currently used in the medical field.
491 citations
••
TL;DR: QDs are one of the first nanotechnologies to be integrated with the biological sciences and are widely anticipated to eventually find application in a number of commercial consumer and clinical products.
Abstract: This review introduces quantum dots (QDs) and explores their properties, synthesis, applications, delivery systems in biology, and their toxicity. QDs are one of the first nanotechnologies to be integrated with the biological sciences and are widely anticipated to eventually find application in a number of commercial consumer and clinical products. They exhibit unique luminescence characteristics and electronic properties such as wide and continuous absorption spectra, narrow emission spectra, and high light stability. The application of QDs, as a new technology for biosystems, has been typically studied on mammalian cells. Due to the small structures of QDs, some physical properties such as optical and electron transport characteristics are quite different from those of the bulk materials.
450 citations
••
Iran University of Medical Sciences1, Tehran University of Medical Sciences2, Tabriz University of Medical Sciences3, Shahid Beheshti University of Medical Sciences and Health Services4, Kermanshah University of Medical Sciences5, University of Alcalá6, NewYork–Presbyterian Hospital7, Yale University8, Universidad Católica San Antonio de Murcia9, Brigham and Women's Hospital10, Virginia Commonwealth University11, University of Nebraska Medical Center12, Icahn School of Medicine at Mount Sinai13, University of Liverpool14, Aalborg University15
TL;DR: In this paper, the authors evaluated the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU).
Abstract: Importance Thrombotic events are commonly reported in critically ill patients with COVID-19. Limited data exist to guide the intensity of antithrombotic prophylaxis. Objective To evaluate the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU). Design, Setting, and Participants Multicenter randomized trial with a 2 × 2 factorial design performed in 10 academic centers in Iran comparing intermediate-dose vs standard-dose prophylactic anticoagulation (first hypothesis) and statin therapy vs matching placebo (second hypothesis; not reported in this article) among adult patients admitted to the ICU with COVID-19. Patients were recruited between July 29, 2020, and November 19, 2020. The final follow-up date for the 30-day primary outcome was December 19, 2020. Interventions Intermediate-dose (enoxaparin, 1 mg/kg daily) (n = 276) vs standard prophylactic anticoagulation (enoxaparin, 40 mg daily) (n = 286), with modification according to body weight and creatinine clearance. The assigned treatments were planned to be continued until completion of 30-day follow-up. Main Outcomes and Measures The primary efficacy outcome was a composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or mortality within 30 days, assessed in randomized patients who met the eligibility criteria and received at least 1 dose of the assigned treatment. Prespecified safety outcomes included major bleeding according to the Bleeding Academic Research Consortium (type 3 or 5 definition), powered for noninferiority (a noninferiority margin of 1.8 based on odds ratio), and severe thrombocytopenia (platelet count Results Among 600 randomized patients, 562 (93.7%) were included in the primary analysis (median [interquartile range] age, 62 [50-71] years; 237 [42.2%] women). The primary efficacy outcome occurred in 126 patients (45.7%) in the intermediate-dose group and 126 patients (44.1%) in the standard-dose prophylaxis group (absolute risk difference, 1.5% [95% CI, −6.6% to 9.8%]; odds ratio, 1.06 [95% CI, 0.76-1.48];P = .70). Major bleeding occurred in 7 patients (2.5%) in the intermediate-dose group and 4 patients (1.4%) in the standard-dose prophylaxis group (risk difference, 1.1% [1-sided 97.5% CI, −∞ to 3.4%]; odds ratio, 1.83 [1-sided 97.5% CI, 0.00-5.93]), not meeting the noninferiority criteria (Pfor noninferiority >.99). Severe thrombocytopenia occurred only in patients assigned to the intermediate-dose group (6 vs 0 patients; risk difference, 2.2% [95% CI, 0.4%-3.8%];P = .01). Conclusions and Relevance Among patients admitted to the ICU with COVID-19, intermediate-dose prophylactic anticoagulation, compared with standard-dose prophylactic anticoagulation, did not result in a significant difference in the primary outcome of a composite of adjudicated venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or mortality within 30 days. These results do not support the routine empirical use of intermediate-dose prophylactic anticoagulation in unselected patients admitted to the ICU with COVID-19. Trial Registration ClinicalTrials.gov Identifier:NCT04486508
447 citations
••
TL;DR: Some of the key regulatory molecules that control the apoptotic pathways, extrinsic and intrinsic death receptors, discuss how defects in apoptosis pathways contribute to cancer, and list several agents being developed to target apoptosis are introduced.
Abstract: Programmed cell death (PCD) or apoptosis is a mechanism which is crucial for all multicellular organisms to control cell proliferation and maintain tissue homeostasis as well as eliminate harmful or unnecessary cells from an organism. Defects in the physiological mechanisms of apoptosis may contribute to different human diseases like cancer. Identification of the mechanisms of apoptosis and its effector proteins as well as the genes responsible for apoptosis has provided a new opportunity to discover and develop novel agents that can increase the sensitivity of cancer cells to undergo apoptosis or reset their apoptotic threshold. These novel targeted therapies include those targeting anti-apoptotic Bcl-2 family members, p53, the extrinsic pathway, FLICE-inhibitory protein (c-FLIP), inhibitor of apoptosis (IAP) proteins, and the caspases. In recent years a number of these novel agents have been assessed in preclinical and clinical trials. In this review, we introduce some of the key regulatory molecules that control the apoptotic pathways, extrinsic and intrinsic death receptors, discuss how defects in apoptotic pathways contribute to cancer, and list several agents being developed to target apoptosis.
405 citations
Authors
Showing all 11569 results
Name | H-index | Papers | Citations |
---|---|---|---|
Theo Vos | 156 | 502 | 186409 |
Derrick A Bennett | 90 | 233 | 120764 |
Mohammad Abdollahi | 90 | 1045 | 35531 |
Albert Gjedde | 85 | 548 | 28653 |
Nassim Kamar | 73 | 628 | 20442 |
Nima Rezaei | 72 | 1215 | 26295 |
Alireza Khataee | 68 | 525 | 20805 |
William E. Acree | 66 | 958 | 21196 |
Mohammad Athar | 63 | 329 | 14384 |
Amir H. Mohammadi | 62 | 698 | 16044 |
Ali Montazeri | 61 | 625 | 17494 |
Ali Nokhodchi | 55 | 322 | 9087 |
Muhammad Naveed | 54 | 346 | 10376 |
Behrooz Z. Alizadeh | 52 | 189 | 13793 |
Mohammad Reza Zali | 51 | 804 | 12541 |